novartis - dofaq.co
Morphosys says takeover by Novartis on course after report of drug safety concern
Reuters - 29 Apr 2024
Morphosys says takeover by Novartis on course after report of drug safety concern ...
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition
STAT - 28 Apr 2024
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition ...
Novartis pays PeptiDream $180M as radiopharma big bang continues
Fierce Biotech - 30 Apr 2024
Novartis pays PeptiDream $180M as radiopharma big bang continues ...
Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies ...
Medicines for Malaria Venture - 24 Apr 2024
Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies ... ...
Research and development
Novartis - 08 Feb 2024
Research and development ...
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
BioSpace - 29 Apr 2024
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT ...
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
FiercePharma - 26 Apr 2024
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia ...
Novartis reports 25% increase in net income in Q1 2024
Pharmaceutical Technology - 24 Apr 2024
Novartis reports 25% increase in net income in Q1 2024 ...
Morphosys says Novartis takeover progressing as planned for H1 2024
XM - 29 Apr 2024
Morphosys says Novartis takeover progressing as planned for H1 2024 ...
Research disease areas
Novartis - 08 Feb 2024
Research disease areas ...
Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO
FiercePharma - 23 Apr 2024
Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO ...
Novartis raises guidance after beating Q1 expectations
Reuters - 23 Apr 2024
Novartis raises guidance after beating Q1 expectations ...
Novartis in Society Integrated Report
Novartis - 31 Jan 2024
Novartis in Society Integrated Report ...
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair
FiercePharma - 23 Apr 2024
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair ...
Novartis 2023 Financial Results
Novartis - 31 Jan 2024
Novartis 2023 Financial Results ...
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs
FiercePharma - 23 Apr 2024
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs ...
Community exploration and learning lab (CELL)
Novartis - 08 Feb 2024
Community exploration and learning lab (CELL) ...
Our commitment to ethical and responsible use of AI
Novartis - 07 Dec 2023
Our commitment to ethical and responsible use of AI ...
Careers in research and development
Novartis - 08 Feb 2024
Careers in research and development ...